Humacyte Stock (NASDAQ:HUMA)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$1.46

52W Range

$1.15 - $9.97

50D Avg

$2.41

200D Avg

$4.74

Market Cap

$221.82M

Avg Vol (3M)

$3.58M

Beta

1.62

Div Yield

-

HUMA Company Profile


Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

218

IPO Date

Dec 01, 2020

Website

HUMA Performance


HUMA Financial Summary


Dec 24Dec 23Dec 22
Revenue--$1.56M
Operating Income$-114.40M$-100.05M$-84.58M
Net Income-$-110.78M$64.22M
EBITDA$-114.40M$-96.46M$2.49M
Basic EPS$-1.26$-1.07$0.62
Diluted EPS$-1.26$-1.07$0.62

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Mar 28, 25 | 8:30 AM
Q3 24Nov 09, 24 | 8:30 AM
Q2 24Aug 13, 24 | 8:30 AM

Peer Comparison


TickerCompany
KALVKalVista Pharmaceuticals, Inc.
HCWBHCW Biologics Inc.
MNOVMediciNova, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals, Inc.
IMCRImmunocore Holdings plc
QSIQuantum-Si incorporated
KURAKura Oncology, Inc.
SEERSeer, Inc.
LYRALyra Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
GPCRStructure Therapeutics Inc.
LRMRLarimar Therapeutics, Inc.
CYTKCytokinetics, Incorporated
VRDNViridian Therapeutics, Inc.